HEMOGENYX PLC (LON:HEMO)
SECTOR – HEALTHCARE
RATING – CORP*
MARKET CAP – £10.9m
CURRENT PRICE – 2.9p#
ANALYSTS: LIAM GASCOIGNE-COHEN
Year-end Dec
2016A
2017A
2018E
2019E
2020E
Revenue (£m)
-
-
No forecasts provided
EBITDA (£m)
(0.5)
(2.3)
Pre-tax profit (£m)
(0.5)
(2.4)
EPS (p)
(0.00)
(0.01)
DPS (p)
-
-
Net Cash/(Debt) (£m)
(0.2)
1.9
P/E (x)
-
-
Dividend yield (%)
-
-
EV/EBITDA (x)
-
-
SOURCE: Northland Capital Partners Limited estimates. #Priced at prior trading day close. *Northland Capital Partners Limited provides acts as Joint Broker to Hemogenyx plc and therefore this information should be viewed as a Marketing Communication.
Initiation of research: Disrupting current blood disease therapy (Note attached)
NORTHLAND VIEW
Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.
- Modular platform technology: The Company is developing two products including an immunotherapy product (CDX Ab) for patient conditioning and a cell therapy (Hu-PHEC) for bone-marrow transplants.
- Clear Milestones: With an established proof-of-principle for its CDX antibody platform, the Company is targeting the start of clinical trials in 2019.
- Revenue-generating collaborations: With collaboration agreements signed across its pipeline, the Company is leveraging its platforms with large industry players to accelerate development and share the cost of development. This represents a strong validation of the Group’s products.
Although the Company has demonstrated strong progress across its pipeline, the share price remains below its IPO price of 3.5p/share. With multiple collaboration agreements and investment from industry we view the Company as undervalued.
COMPANY DESCRIPTION
Preclinical stage biotechnology company focused on the development of novel therapies for blood diseases.